These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 9143945)

  • 1. Baseline HIV type 1 load predicts the long-term clinical outcome of infected patients. The 'positive feedback theory'.
    Briant L; Devaux C
    Immunol Lett; 1997 Feb; 55(2):123-5. PubMed ID: 9143945
    [No Abstract]   [Full Text] [Related]  

  • 2. Increased soluble Fas in HIV-infected hemophilia patients with CD4+ and CD8+ cell count increases and viral load and immune complex decreases.
    Daniel V; Süsal C; Weimer R; Zimmermann R; Huth-Kühne A; Opelz G
    AIDS Res Hum Retroviruses; 2001 Mar; 17(4):329-35. PubMed ID: 11242519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of HIV-1 infection and preservation of CD4 function by the binding of CPFs to gp120.
    Finberg RW; Diamond DC; Mitchell DB; Rosenstein Y; Soman G; Norman TC; Schreiber SL; Burakoff SJ
    Science; 1990 Jul; 249(4966):287-91. PubMed ID: 2115689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AIDS/HIV. Developing an AIDS vaccine: need, uncertainty, hope.
    Emini EA; Koff WC
    Science; 2004 Jun; 304(5679):1913-4. PubMed ID: 15218131
    [No Abstract]   [Full Text] [Related]  

  • 5. Detection of IgA inhibiting the interaction between gp120 and soluble CD4 receptor in serum and saliva of HIV-1-infected patients.
    Vincent N; Malvoisin E; Pozzetto B; Lucht F; Genin C
    AIDS; 2004 Jan; 18(1):37-43. PubMed ID: 15090827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Covalently crosslinked complexes of human immunodeficiency virus type 1 (HIV-1) gp120 and CD4 receptor elicit a neutralizing immune response that includes antibodies selective for primary virus isolates.
    Devico A; Silver A; Thronton AM; Sarngadharan MG; Pal R
    Virology; 1996 Apr; 218(1):258-63. PubMed ID: 8615032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term survivors.
    Betts MR; Krowka JF; Kepler TB; Davidian M; Christopherson C; Kwok S; Louie L; Eron J; Sheppard H; Frelinger JA
    AIDS Res Hum Retroviruses; 1999 Sep; 15(13):1219-28. PubMed ID: 10480635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunologic and virologic analyses of an acutely HIV type 1-infected patient with extremely rapid disease progression.
    Demarest JF; Jack N; Cleghorn FR; Greenberg ML; Hoffman TL; Ottinger JS; Fantry L; Edwards J; O'Brien TR; Cao K; Mahabir B; Blattner WA; Bartholomew C; Weinhold KJ
    AIDS Res Hum Retroviruses; 2001 Sep; 17(14):1333-44. PubMed ID: 11602044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unique binding modes for the broad neutralizing activity of single-chain variable fragments (scFv) targeting CD4-induced epitopes.
    Tanaka K; Kuwata T; Alam M; Kaplan G; Takahama S; Valdez KPR; Roitburd-Berman A; Gershoni JM; Matsushita S
    Retrovirology; 2017 Sep; 14(1):44. PubMed ID: 28938888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission.
    Derdeyn CA; Decker JM; Bibollet-Ruche F; Mokili JL; Muldoon M; Denham SA; Heil ML; Kasolo F; Musonda R; Hahn BH; Shaw GM; Korber BT; Allen S; Hunter E
    Science; 2004 Mar; 303(5666):2019-22. PubMed ID: 15044802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. gp120-directed antibody-dependent cellular cytotoxicity as a major determinant of the rate of decline in CD4 percentage in HIV-1 disease.
    Skowron G; Cole BF; Zheng D; Accetta G; Yen-Lieberman B
    AIDS; 1997 Dec; 11(15):1807-14. PubMed ID: 9412698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The monoclonal CD4 antibody M-T413 inhibits cellular infection with human immunodeficiency virus after viral attachment to the cell membrane: an approach to postexposure prophylaxis.
    Rieber EP; Federle C; Reiter C; Krauss S; Gürtler L; Eberle J; Deinhardt F; Riethmüller G
    Proc Natl Acad Sci U S A; 1992 Nov; 89(22):10792-6. PubMed ID: 1438278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiviral Activity of HIV gp120-Targeting Bispecific T Cell Engager Antibody Constructs.
    Brozy J; Schlaepfer E; Mueller CKS; Rochat MA; Rampini SK; Myburgh R; Raum T; Kufer P; Baeuerle PA; Muenz M; Speck RF
    J Virol; 2018 Jul; 92(14):. PubMed ID: 29720517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolation and characterization of a novel neutralizing antibody targeting the CD4-binding site of HIV-1 gp120.
    Qiao Y; Man L; Qiu Z; Yang L; Sun Y; He Y
    Antiviral Res; 2016 Aug; 132():252-61. PubMed ID: 27387828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in human immunodeficiency virus 1-infected humans.
    Kang CY; Nara P; Chamat S; Caralli V; Ryskamp T; Haigwood N; Newman R; Köhler H
    Proc Natl Acad Sci U S A; 1991 Jul; 88(14):6171-5. PubMed ID: 2068099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Saliva can mediate HIV-1-specific antibody-dependent cell-mediated cytotoxicity.
    Kim JS; Nag P; Landay AL; Alves M; Cohn MH; Bremer JW; Baum LL
    FEMS Immunol Med Microbiol; 2006 Nov; 48(2):267-73. PubMed ID: 16978244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defective killing activity against gp120/41-expressing human erythroleukaemic K562 cell line by monocytes and natural killer cells from HIV-infected individuals.
    Ahmad A; Menezes J
    AIDS; 1996 Feb; 10(2):143-9. PubMed ID: 8838701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies.
    Ly A; Stamatatos L
    J Virol; 2000 Aug; 74(15):6769-76. PubMed ID: 10888615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enzyme immunoassay (ELISA) for the evaluation of antibodies directed to the CD4 receptor-binding site of the HIV gp120 molecule.
    Hinkula J; Gidlund M; Persson C; Osterhaus A; Wahren B
    J Immunol Methods; 1994 Sep; 175(1):37-46. PubMed ID: 7523525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of anti-CD4 idiotype vaccination in HIV positive volunteers.
    Schedel I; Sutor GC; Hunsmann G; Jurkiewicz E
    Vaccine; 1999 Apr; 17(15-16):1837-45. PubMed ID: 10217581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.